Obesity meeting data: Lilly, Novo, Regeneron and rivals sharpen strategies

· Health

At a European obesity scientific meeting, Eli Lilly impressed with amylin-Zepbound combination data, Novo demonstrated continued weight loss after a switch to oral treatment, and AbbVie and Boehringer gave glimpses into their contenders. Regeneron said it sees a future combining its obesity drug with lipid-lowering therapy as it seeks a differentiating factor.

Why it matters：With GLP-1 drugs approaching late-stage trials and stronger weight-loss results, the meeting data signals how competitors plan to differentiate in a crowded obesity market.

Key points

  • Lilly presented amylin-Zepbound combination data.
  • Novo showed continued weight loss after patients switched to an oral treatment.
  • Regeneron is pursuing a combination with lipid-lowering therapy as a differentiator.

Sources (original reporting)

More stories from this day